

Edgar Filing: ENZO BIOCHEM INC - Form 8-K

ENZO BIOCHEM INC
Form 8-K
March 14, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): MARCH 13, 2006

ENZO BIOCHEM, INC.

(Exact Name of Registrant as Specified in Its Charter)

NEW YORK

(State or Other Jurisdiction of Incorporation)

001-09974

13-2866202

(Commission File Number)

(IRS Employer Identification No.)

60 EXECUTIVE BOULEVARD
FARMINGDALE, NEW YORK

11735

(Address of Principal Executive Offices)

(Zip Code)

(631) 755-5500

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (SEE General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: ENZO BIOCHEM INC - Form 8-K

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

(a) The following information, including the Exhibit attached hereto, is being furnished pursuant to this Item 2.02 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

On March 13, 2006, Enzo Biochem, Inc., a New York corporation (the "Company"), issued a press release discussing its financial results for its second fiscal quarter ended January 31, 2006. A copy of the press release is furnished as Exhibit 99.1 to this report.

ITEM 8.01. OTHER EVENTS.

On March 14, 2006, the Company issued a press release announcing that its wholly owned subsidiary Enzo Therapeutics has initiated a Phase II clinical trial to evaluate its immunomodulatory candidate drug EGS21 as a therapeutic for managing Crohn's disease. A Phase I safety trial of EGS21 was successfully concluded last year. The study is being conducted at Hebrew University Hadassah Medical Center where subject enrollment is proceeding. The press release issued by the Company announcing the foregoing is included as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference in its entirety into this Item 8.01.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

Exhibit No. -----	Description -----
99.1	Press Release of Enzo Biochem, Inc., dated March 13, 2006, discussing financial results for second fiscal quarter ended January 31, 2006.
99.2	Press Release of Enzo Biochem, Inc., dated March 14, 2006, announcing initiation of Phase II clinical trial.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENZO BIOCHEM, INC.

Date: March 13, 2006

By: /s/ Barry Weiner

Barry Weiner
President and Chief Financial Officer

Edgar Filing: ENZO BIOCHEM INC - Form 8-K

EXHIBIT INDEX

Exhibit No. -----	Description -----
99.1	Press Release of Enzo Biochem, Inc., dated March 13, 2006, discussing financial results for second fiscal quarter ended January 31, 2006.
99.2	Press Release of Enzo Biochem, Inc., dated March 14, 2006, announcing initiation of Phase II clinical trial.